Rationale: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis (MDA5-DM) is an autoimmune disease, characterized by a particular skin ulcer and rapidly progressive interstitial lung disease (RP-ILD). This case highlights diagnostic challenges of this disease and underscores the importance of early recognition and timely intervention. Patient concerns: A 59-year-old woman presented to the hospital with systemic myalgia, fatigue, and anorexia. Following admission she developed recurrent fever. Computed tomography of the chest and bronchoalveolar lavage fluid analysis revealed severe pulmonary infections. Despite 2 weeks of antimicrobial therapy yielding radiographic improvement, her dermatomyositis symptoms worsened. Diagnoses: Immune profiling and myositis-specific antibody testing confirmed the diagnosis of MDA5-DM-ILD. Interventions: The following treatment included methylprednisolone combined with immunosuppressants (tofacitinib, tacrolimus, tocilizumab, mycophenolate mofetil). Subsequent computed tomography imaging demonstrated cavity lesions and micronodules, with lung biopsy confirming fungal and viral coinfections. Therapy was adjusted to sustained methylprednisolone (22 mg/d), tacrolimus (0.5 g/d), targeted antimicrobials (ganciclovir, voriconazole) and prophylactic use of sulfamethoxazole complex. Outcomes: At discharge, the patient achieved clinical stability with resolved fever, normalized oxygen saturation and improved myalgia, though mild epigastric discomfort persisted. Lessons: MDA5-DM-ILD poses challenges for clinicians due to its diagnostic difficulty, rapid progression and secondary infection risks. Early immunosuppression combined with infection prevention is the key to a successful treatment of this disease.
9 October 2024 in Frontiers in Cellular and Infection Microbiology
Rampant C-to-U RNA editing drives the mutation and evolution of SARS-CoV-2. While much attention has been paid to missense mutations, the C-to-U events leading to AUG and thus creating novel ORFs were uninvestigated. By utilizing the public time-course mutation data from the worldwide SARS-CoV-2 population, we systematically identified the “AUG-gain mutations” caused by C-to-U RNA editing. Synonymous mutations were of special focus. A total of 58 synonymous C-to-U sites are able to create out-of-frame AUG in coding sequence (CDS). These 58 synonymous sites showed significantly higher allele frequency (AF) and increasing rate (dAF/dt) than other C-to-U synonymous sites in the SARS-CoV-2 population, suggesting that these 58 AUG-gain events conferred additional benefits to the virus and are subjected to positive selection. The 58 predicted new ORFs created by AUG-gain events showed the following advantages compared to random expectation: they have longer lengths, higher codon adaptation index (CAI), higher Kozak scores, and higher tRNA adaptation index (tAI). The 58 putatively novel ORFs have high expressibility and are very likely to be functional, providing an explanation for the positive selection on the 58 AUG-gain mutations. Our study proposed a possible mechanism of the emergence of de novo genes in SARS-CoV-2. This idea should be helpful in studying the mutation and evolution of SARS-CoV-2.
Introduction: Lung cancer is a leading cause of cancer‐related deaths, with an annual mortality rate of nearly 1.8 million. Among its subtypes, lung adenocarcinoma is increasingly prevalent. Due to its often asymptomatic nature, most patients are diagnosed at advanced stages, missing the optimal window for surgery and resulting in a poor 5‐year survival rate.Case Presentation: We present the case of an 83‐year‐old patient with stage IV lung adenocarcinoma treated with four cycles of intravenous Tirelizumab and two cycles of intratumoral Tirelizumab via tracheoscopy. The patient achieved partial clinical remission, with tumor lesions continuing to shrink upon follow‐up by August 24, 2024. No treatment‐related adverse reactions were observed, and the patient's immune function remained normal.Conclusions: This case suggests that systemic intravenous Tirelizumab combined with tracheoscopic intratumoral injection may offer a safe and effective treatment strategy for lung adenocarcinoma, particularly for patients unsuitable for chemotherapy or surgery. However, further prospective studies and clinical trials are needed to validate these findings.